查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2003550

全球生物保存市场：按产品、应用、细胞供应和地区划分－市场规模、产业动态、机会分析和预测（2026-2035 年）

Global Biopreservation Market: By Product, Application, Cell Providers Volume, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 290 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球生物保存市场目前正经历着一场根本性的模式转移，反映了生命科学和先进治疗方法的快速发展及其日益增长的重要性。预计到2025年，该市场规模将达到45.2亿美元，并有望迎来爆发性成长，预计到2035年将飙升至444.5亿美元。这一显着成长意味着在2026年至2035年的预测期内，复合年增长率将达到25.68%，凸显了生物保存产业蓬勃发展的快速势头。

市场价值的飙升主要得益于再生医学、干细胞研究以及细胞和基因治疗（CGT）商业化领域的重大突破和积极发展。这些前沿领域正在革新医学，为治疗以往被认为无法治癒的复杂疾病和病症提供了新的方法。随着再生医学和CGT的不断成熟，对先进可靠的生物保存解决方案的需求也日益增长。

显着的市场趋势

生物保存市场正经历主要企业之间的适度整合，一级企业如赛默飞世尔科技（Thermo Fisher Scientific）、默克集团（Merck KGaA）和安万特（Avanter，现为VWR）在硬体和通用耗材领域占据了显着的市场份额。这些行业领导者透过提供涵盖所有生物保存需求的全面整合解决方案，确立了自身的市场主导地位。他们的策略方针强调提供「端到端」服务，使客户能够以单一整合包的形式购买从冷冻库、储存管瓶到特种培养基和高级追踪软体等所有产品。

近年来，这些市场领导加大了对创新的投入，尤其是在「智慧」整合技术的研发方面。这一趋势反映了市场对智慧生物保存系统日益增长的需求，这些系统不仅要具备可靠性，还要能够实现无缝通讯和自动化管理。例如，一些新型冷冻培养基配方应运而生，这些配方专为支援自动化处理而设计。这些培养基的黏度通常较低，从而能够更顺畅地进行机器人操作，并降低自动化工作流程中样品受损的风险。

同时，冷冻库技术的进步也解决了样品安全和灾害预防的关键问题。製造商现在提供的冷冻库配备了整合式备用冷却系统，例如液态氮（LN2）注入装置，即使在断电或机械故障的情况下也能维持超低温。这些备用系统提供了必要的安全措施，防止温度波动对珍贵且往往不可取代的生物样本造成损害。

主要成长驱动因素

生物保存市场成长的主要驱动力是持续推进的再生医学革命。在细胞疗法和基因疗法突破性进展的推动下，这场变革性运动正在重塑医药和医疗保健格局。美国食品药物管理局（FDA）和欧洲药品管理局（EMA）等监管机构正在加速核准创新治疗方法，包括CAR-T（嵌合体抗原受体T细胞）疗法。 CAR-T疗法利用患者自身的免疫细胞标靶并摧毁癌细胞。

新机会的趋势

生物保存市场真正的「蓝海」机会在于常温保存技术的开发与应用。这些创新方法能够在常温下实现干燥和化学稳定，并有望彻底革新生物样本的保存方式，摆脱对传统低温保存方法的依赖。目前，生物保存产业严重依赖液态氮（LN2）和其他低温工艺，这些工艺需要专用设备、持续的温度监控以及巨大的能源消耗。常温保存技术可望从根本上改变这种低温运输模式，提供更便利、更经济、更永续的替代方案。

优化障碍

儘管生物保存市场的成长前景普遍乐观，但该产业仍面临许多挑战，这些挑战可能会阻碍其广泛应用和发展。其中一个最突出的障碍是自动化技术的高成本，这对小规模实验室和学术机构构成了重大阻碍。虽然自动化具有许多优势，包括提高效率、准确性和可重复性，但实施和运行这些先进系统所需的初始投资对于许多预算有限的机构而言仍然难以负担。

目录

第一章执行摘要：全球生物保存市场

第二章：调查方法与研究框架

  • 研究目标
  • 产品概述
  • 市场区隔
  • 定性研究
    • 一手和二手资讯
  • 量化研究
    • 一手和二手资讯
  • 初步调查受访者组成：依地区划分
  • 本研究的先决条件
  • 市场规模估算
  • 数据检验

第三章：全球生物保存市场概览

  • 产业价值链分析
    • 原料供应商（培养基、试剂、冷冻保护剂）
    • 生物保存设备製造商 [SP1.1]
    • 解决方案和文化媒介提供者
    • 生物样本库和储存设施 [SP2.1]
    • 研究机构和合约研究组织
    • 製药和生物技术公司
    • 最终使用者（医院、诊断检查室）
  • 产业展望
    • 对再生医学的需求日益增长
    • 扩大生物银行活动[SP3.1]
    • 器官移植手术增加 [SP4.1]
    • 细胞和基因治疗研究的扩展 [SP5.1]
    • 增加对生物技术领域的投资[SP6.1]
    • 对个人化医疗的需求日益增长 [SP7.1]
    • 冷冻保存技术的进展 [SP8.1]
    • 政府和私部门增加资金筹措
  • PESTLE分析
  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争强度
  • 市场动态和趋势
    • 成长驱动因素
    • 抑制因子
    • 机会
    • 主要趋势
  • 市场成长及前景
    • 2020-2035年市场收益估算与预测
    • 按原物料分析价格趋势

第四章 竞争格局概述

  • 市场集中度
  • 企业市场占有率分析（以金额为准，%），2025 年
  • 竞争对手分析与基准测试
  • Start-Ups生态系分析
  • 併购和资金筹措趋势

第五章：全球生物防腐市场分析

  • 关键见解
  • 市场规模及预测（2020-2035）
    • 副产品
    • 透过使用
    • 按细胞供应量
    • 按地区

第六章：北美生物保存市场分析

第七章：欧洲生物保存市场分析

第八章：亚太地区生物保存市场分析

第九章：中东和非洲生物保存市场分析

第十章：南美洲生物保存市场分析

第十一章：公司简介

  • Azenta US, Inc.
  • BioLife Solutions
  • LabVantage Solutions, Inc.
  • Biomatrica, Inc.
  • MVE Biological Solutions
  • Thermo Fisher Scientific, Inc.
  • Panasonic
  • X-Therma Inc.
  • PrincetonCryo
  • Stirling Ultracold
  • Taylor-Wharton
  • 其他有潜力的企业

第十二章附录

简介目录
Product Code: AA01261689

The global biopreservation market is currently experiencing a profound and transformative paradigm shift, reflecting the rapid evolution and growing importance of life sciences and advanced therapies. Valued at USD 4.52 billion in 2025, the market is poised for exponential growth, with projections estimating its valuation to soar to an impressive USD 44.45 billion by 2035. This remarkable expansion corresponds to a compound annual growth rate (CAGR) of 25.68% over the forecast period from 2026 to 2035, underscoring the dynamic pace at which the biopreservation sector is advancing.

This surge in market value is primarily fueled by significant breakthroughs and heightened activity in regenerative medicine, stem cell research, and the commercialization of cell and gene therapies (CGT). These cutting-edge fields are revolutionizing medical science by offering novel approaches to treat complex diseases and conditions that were previously considered untreatable. As regenerative medicine and CGT continue to mature, the need for sophisticated and reliable biopreservation solutions becomes increasingly critical.

Noteworthy Market Developments

The biopreservation market exhibits a moderate level of consolidation among its leading companies, with Tier 1 players such as Thermo Fisher Scientific, Merck KGaA, and Avantor (VWR) commanding a significant share of the hardware and general consumables segments. These industry giants have established themselves as dominant forces by offering comprehensive, integrated solutions that encompass the full spectrum of biopreservation needs. Their strategic approach focuses on providing "end-to-end" services, where customers can purchase everything from freezers and storage vials to specialized media and advanced tracking software as a cohesive, bundled package.

In recent years, these market leaders have intensified their focus on innovation, particularly through the development of "smart" integration technologies. This trend reflects a growing demand for biopreservation systems that are not only reliable but also intelligent, capable of seamless communication and automated management. For instance, new cryo-media formulations are being introduced that are specifically engineered to support automated handling processes. These media tend to have lower viscosity, which facilitates smoother robotic manipulation and reduces the risk of sample damage during automated workflows.

Simultaneously, advancements in freezer technology are addressing critical concerns related to sample safety and disaster prevention. Manufacturers are launching freezers equipped with integrated backup cooling systems, such as liquid nitrogen (LN2) injection mechanisms, designed to maintain ultra-low temperatures even during power outages or mechanical failures. These backup systems provide an essential safeguard against temperature excursions that could otherwise compromise valuable and often irreplaceable biological samples.

Core Growth Drivers

The primary engine propelling growth in the biopreservation market is the ongoing Regenerative Medicine Revolution. This transformative movement, driven by groundbreaking advancements in cell and gene therapies, is reshaping the pharmaceutical and healthcare landscapes. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accelerated the approval of innovative therapies, including CAR-T (chimeric antigen receptor T-cell) treatments, which harness patients' own immune cells to target and destroy cancer cells.

Emerging Opportunity Trends

The true "Blue Ocean" opportunity within the biopreservation market lies in the development and adoption of room-temperature storage technologies. These innovative approaches have the potential to revolutionize the way biological samples are preserved by enabling desiccation or chemical stabilization at ambient temperatures, thereby eliminating the traditional dependence on ultra-cold storage methods. Currently, the biopreservation industry relies heavily on liquid nitrogen (LN2) and other cryogenic processes, which require specialized equipment, continuous temperature monitoring, and significant energy consumption. Room-temperature storage technologies promise to disrupt this cold chain paradigm entirely, offering a more accessible, cost-effective, and sustainable alternative.

Barriers to Optimization

Despite the prevailing optimism surrounding the growth of the biopreservation market, the industry continues to face significant challenges that could hinder its broader adoption and development. One of the most notable obstacles is the high cost associated with automation technologies, which poses a considerable barrier for smaller laboratories and academic institutions. While automation offers numerous advantages, such as improved efficiency, accuracy, and reproducibility, the initial capital expenditure required to acquire and implement these advanced systems remains prohibitively expensive for many organizations operating with limited budgets.

Detailed Market Segmentation

By product category, the media segment is poised to experience extraordinary growth, with a projected compound annual growth rate (CAGR) of 32% over the forecast period from 2026 to 2035. This remarkable expansion signals one of the most significant value shifts within the bio-preservation and related life sciences industries. It reflects a fundamental change in how companies and laboratories allocate resources, moving away from traditional, capital-intensive investments in hardware toward a greater emphasis on consumable products that require frequent replenishment.

  • In terms of sample volume, the induced pluripotent stem cell (iPSC) segment is anticipated to experience robust growth throughout the forecast period, reflecting its increasing importance and adoption in biomedical research and therapeutic applications. iPSCs have garnered significant attention due to their unique capabilities and advantages over traditional stem cell sources, positioning them as a critical component in the expanding field of regenerative medicine and personalized therapies.

By application, the biobanking category has emerged as the leader in the global bio-preservation market, reflecting its critical role in the evolving landscape of biomedical research and therapy development. As of 2025, the dialogue surrounding bio-preservation has transformed significantly, moving beyond the traditional notion of mere "storage" of biological materials to a more strategic focus on supply chain resilience. This shift acknowledges the importance of bio-preservation not just as a passive repository but as an active component in ensuring the availability, integrity, and timely distribution of critical biological samples and materials across complex therapeutic networks.

Segment Breakdown

By Product

  • Equipment
  • Refrigerators
  • Freezers
  • Consumables
  • Straws
  • Vials
  • Microtiter Plates
  • Bags
  • Liquid Nitrogen
  • Media
  • Home-brew
  • Pre-formulated
  • Laboratory Information Management System (LIMS)

By Application

  • Regenerative Medicine
  • Gene Therapy
  • Cell Therapy
  • Others
  • Bio-banking
  • Human Sperms
  • Human Eggs
  • Veterinary IVF
  • Drug Discovery

By Cell Providers Volume

  • CD19+
  • CD34+
  • iPSC
  • MSC
  • Tumor Cells
  • hESC
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Geography Breakdown

  • North America stands as the mature innovator within the global pharmaceutical and biotechnology landscape, contributing over 47% of the total market revenue. This region's dominant position is the result of several interrelated factors, including substantial investment in research and development (R&D) and the concentration of major pharmaceutical conglomerates headquartered within its borders. These elements combine to create a robust ecosystem that fosters innovation, accelerates the development of cutting-edge therapies, and sustains the region's leadership in the global market.
  • The United States, in particular, serves as the global epicenter for cell therapy development. This leadership role is supported by the presence of critical regulatory and funding institutions such as the Food and Drug Administration (FDA) and the National Institutes of Health (NIH). Together, these organizations establish a rigorous but well-resourced environment that promotes scientific advancement while ensuring patient safety and regulatory compliance. The FDA's stringent approval processes, combined with the NIH's substantial research funding, create a balanced framework that encourages innovation while maintaining high standards.

Leading Market Participants

  • Azenta US, Inc.
  • BioLife Solutions
  • LabVantage Solutions, Inc.
  • Biomatrica, Inc.
  • MVE Biological Solutions
  • Thermo Fisher Scientific, Inc.
  • Panasonic
  • X-Therma Inc.
  • PrincetonCryo
  • Stirling Ultracold
  • Taylor-Wharton
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Biopreservation Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Biopreservation Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material Suppliers (Media, Reagents, Cryoprotectants)
    • 3.1.2. Biopreservation Equipment Manufacturers[SP1.1]
    • 3.1.3. Solution & Media Providers
    • 3.1.4. Biobanks & Storage Facilities[SP2.1]
    • 3.1.5. Research Institutes & CROs
    • 3.1.6. Pharmaceutical & Biotechnology Companies
    • 3.1.7. End Users (Hospitals, Diagnostic Labs)
  • 3.2. Industry Outlook
    • 3.2.1. Rising Demand for Regenerative Medicine
    • 3.2.2. Growth in Biobanking Activities[SP3.1]
    • 3.2.3. Increasing Organ Transplantation Procedures[SP4.1]
    • 3.2.4. Expansion of Cell & Gene Therapy Research[SP5.1]
    • 3.2.5. Rising Investments in Biotechnology Sector[SP6.1]
    • 3.2.6. Growing Demand for Personalized Medicine[SP7.1]
    • 3.2.7. Technological Advancements in Cryopreservatio[SP8.1]n
    • 3.2.8. Increasing Government & Private Funding
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Dynamics and Trends
    • 3.5.1. Growth Drivers
      • 3.5.1.1. Rising Demand for Regenerative Medicine
    • 3.5.2. Restraints
    • 3.5.3. Opportunity
    • 3.5.4. Key Trend
  • 3.6. Market Growth and Outlook
    • 3.6.1. Market Revenue & Volume Estimates and Forecast (US$ Mn), 2020 - 2035
    • 3.6.2. Price Trend Analysis, by Feedstock

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking
  • 4.4. Startup Ecosystem Analysis
  • 4.5. M&A and Funding Landscape

Chapter 5. Global Biopreservation Market Analysis

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Product
      • 5.2.1.1. Equipment
        • 5.2.1.1.1. Refrigerators
        • 5.2.1.1.2. Freezers
        • 5.2.1.1.3. Consumables
          • 5.2.1.1.3.1. Straws
          • 5.2.1.1.3.2. Vials
          • 5.2.1.1.3.3. Microtiter Plates
        • 5.2.1.1.4. Bags
        • 5.2.1.1.5. Liquid Nitrogen
      • 5.2.1.2. Media
        • 5.2.1.2.1. Home-brew
        • 5.2.1.2.2. Pre-formulated
      • 5.2.1.3. Laboratory Information Management System (LIMS)
    • 5.2.2. By Application
      • 5.2.2.1. Regenerative Medicine
        • 5.2.2.1.1. Gene Therapy
        • 5.2.2.1.2. Cell Therapy
        • 5.2.2.1.3. Others
      • 5.2.2.2. Bio-banking
        • 5.2.2.2.1. Human Sperms
        • 5.2.2.2.2. Human Eggs
        • 5.2.2.2.3. Veterinary IVF
      • 5.2.2.3. Drug Discovery
    • 5.2.3. By Cell Providers Volume
      • 5.2.3.1. CD19+
      • 5.2.3.2. CD34+
      • 5.2.3.3. IPSC
      • 5.2.3.4. MSC
      • 5.2.3.5. Tumor Cells
      • 5.2.3.6. HESC
      • 5.2.3.7. Others
    • 5.2.4. By Region
      • 5.2.4.1. North America
        • 5.2.4.1.1. The U.S.
        • 5.2.4.1.2. Canada
        • 5.2.4.1.3. Mexico
      • 5.2.4.2. Europe
        • 5.2.4.2.1. Western Europe
          • 5.2.4.2.1.1. The UK
          • 5.2.4.2.1.2. Germany
          • 5.2.4.2.1.3. France
          • 5.2.4.2.1.4. Italy
          • 5.2.4.2.1.5. Spain
          • 5.2.4.2.1.6. Rest of Western Europe
        • 5.2.4.2.2. Eastern Europe
          • 5.2.4.2.2.1. Poland
          • 5.2.4.2.2.2. Russia
          • 5.2.4.2.2.3. Rest of Eastern Europe
      • 5.2.4.3. Asia Pacific
        • 5.2.4.3.1. China
        • 5.2.4.3.2. India
        • 5.2.4.3.3. Japan
        • 5.2.4.3.4. South Korea
        • 5.2.4.3.5. Australia & New Zealand
        • 5.2.4.3.6. ASEAN
          • 5.2.4.3.6.1. Indonesia
          • 5.2.4.3.6.2. Malaysia
          • 5.2.4.3.6.3. Thailand
          • 5.2.4.3.6.4. Singapore
          • 5.2.4.3.6.5. Rest of ASEAN
        • 5.2.4.3.7. Rest of Asia Pacific
      • 5.2.4.4. Middle East & Africa
        • 5.2.4.4.1. UAE
        • 5.2.4.4.2. Saudi Arabia
        • 5.2.4.4.3. South Africa
        • 5.2.4.4.4. Rest of MEA
      • 5.2.4.5. South America
        • 5.2.4.5.1. Argentina
        • 5.2.4.5.2. Brazil
        • 5.2.4.5.3. Rest of South America

Chapter 6. North America Biopreservation Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By Cell Providers Volume
    • 6.2.4. By Country

Chapter 7. Europe Biopreservation Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By Cell Providers Volume
    • 7.2.4. By Country

Chapter 8. Asia Pacific Biopreservation Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By Cell Providers Volume
    • 8.2.4. By Country

Chapter 9. Middle East & Africa Biopreservation Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By Cell Providers Volume
    • 9.2.4. By Country

Chapter 10. South America Biopreservation Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By Cell Providers Volume
    • 10.2.4. By Country

Chapter 11. Company Profile ([SP9.1]Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Azenta US, Inc.
  • 11.2. BioLife Solutions
  • 11.3. LabVantage Solutions, Inc.
  • 11.4. Biomatrica, Inc.
  • 11.5. MVE Biological Solutions
  • 11.6. Thermo Fisher Scientific, Inc.
  • 11.7. Panasonic
  • 11.8. X-Therma Inc.
  • 11.9. PrincetonCryo
  • 11.10. Stirling Ultracold
  • 11.11. Taylor-Wharton
  • 11.12. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Macro-Economic Outlook/Indicators